AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30963179 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy (FHT)
Number of subjects: 0
Study 30963212 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nab-PTX 260 mg/m2 with trastuzumab every 3 weeks for four cycles
Number of subjects: 18
Study 30963506 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (140-mg subcutaneous dose)
Number of subjects: 0
Study 30963506 — intervention group
Group type: COMPARATOR
Intervention: Norgestimate/ethinyl estradiol-containing oral contraceptive
Number of subjects: 0
Study 30963691 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib (80 or 150 mg BID for 14 days per 28-day cycle)
Number of subjects: 149
Study 30964425 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Mammography plus Tomosynthesis (DM plus DBT)
Number of subjects: 0
Study 30964425 — intervention group
Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 0
Study 30964436 — intervention group
Group type: EXPERIMENTAL
Intervention: e-message intervention (3 to 4 electronic weekly messages)
Number of subjects: 128
Study 30964439 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of monthly telephone calls for 6 months by a case manager and weekly, one-way informational text messages.
Number of subjects: 141
Study 30964439 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of 4 or more phone calls during the intervention.
Number of subjects: 141
Study 30964819 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Saccharomyces cerevisiae mannan antibodies (ASCA)
Number of subjects: 43
Study 30964819 — intervention group
Group type: EXPERIMENTAL
Intervention: Outer membrane porin C (OmpC)
Number of subjects: 43
Study 30964819 — intervention group
Group type: COMPARATOR
Intervention: CBir1
Number of subjects: 43
Study 30964819 — intervention group
Group type: COMPARATOR
Intervention: Antineutrophil cytoplasmic antibodies
Number of subjects: 43
Study 30965011 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-Dose Alpha-1 Antitrypsin Augmentation Therapy
Number of subjects: 0
Study 30965011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30965288 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern breath sampling system (Pneumopipe)
Number of subjects: 0
Study 30967392 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib plus ofatumumab
Number of subjects: 27
Study 30967435 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline serum uric acid (SUA)
Number of subjects: 539
Study 30967831 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day for 5 consecutive days at baseline and 3 consecutive days 12 months later)
Number of subjects: 0
Study 30967831 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 30967831 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring strategies for alemtuzumab-treated patients
Number of subjects: 0
Study 30968056 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aH5N1c vaccine (7.5 μg of hemagglutinin antigen per dose)
Number of subjects: 2372
Study 30968056 — intervention group
Group type: COMPARATOR
Intervention: Half-dose aH5N1c vaccine
Number of subjects: 2372
Study 30968056 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aH5N1c vaccine
Number of subjects: 2372
Study 30968114 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet (highest quartile)
Number of subjects: 50884
Study 30968114 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010 (highest quartile)
Number of subjects: 50884
Study 30968114 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010 (highest quartile, excluding alcohol)
Number of subjects: 50884
Study 30968114 — intervention group
Group type: EXPERIMENTAL
Intervention: AMED (highest quartile)
Number of subjects: 50884
Study 30968129 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal obesity (BMI ≥25 kg/m2)
Number of subjects: 35
Study 30968137 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein intake (highest vs lowest quartile)
Number of subjects: 2641
Study 30968137 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein intake (highest vs lowest quartile)
Number of subjects: 2641
Study 30968137 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-to-plant protein ratio (extreme quartile)
Number of subjects: 2641
Study 30968137 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake (extreme quartile)
Number of subjects: 2641
Study 30968137 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein intake among those with disease history
Number of subjects: 2641
Study 30968255 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training combined with chemotherapy
Number of subjects: 10
Study 30968255 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 10
Study 30968255 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 10
Study 30968301 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet expression of FcγRIIa in patients after MI
Number of subjects: 114
Study 30968301 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 114
Study 30968301 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet agent cangrelor
Number of subjects: 114
Study 30968368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir monotherapy
Number of subjects: 36
Study 30968368 — intervention group
Group type: COMPARATOR
Intervention: Combination antiretroviral therapy (cART) with efavirenz/emtricitabine/tenofovir
Number of subjects: 36
Study 30968800 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccade task performance
Number of subjects: 57
Study 30968800 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanker task performance
Number of subjects: 57
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Emergency Team (MET) activations
Number of subjects: 1664
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Emergency Team (MET) operational time
Number of subjects: 1664
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: Average mission time of MET
Number of subjects: 1664
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary reason for MET activation
Number of subjects: 1664
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: MET deployments for emergencies at weekends
Number of subjects: 1664
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls for cardiopulmonary resuscitation (CPR)
Number of subjects: 1664
Study 30969357 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of in-hospital cardiac arrests
Number of subjects: 1664
Study 30969486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention programme with whey supplements (30 g/day) and personalized resistance training regimen for 32 elderly subjects from the sarcopenic cohort.
Number of subjects: 56
Study 30969486 — intervention group
Group type: COMPARATOR
Intervention: High levels of TNF-α (>11.15 pg/mL) and TWEAK (>1276.48 pg/mL) in sarcopenic patients.
Number of subjects: 56
Study 30969486 — intervention group
Group type: COMPARATOR
Intervention: Comparison of serum levels of proinflammatory cytokines and metabolic hormones between sarcopenic and non-sarcopenic subjects.
Number of subjects: 56
Study 30971168 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic carotid plaques
Number of subjects: 0
Study 30971168 — intervention group
Group type: COMPARATOR
Intervention: Contralateral side (control)
Number of subjects: 0
Study 30971227 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 93
Study 30971261 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma-related crisis events (A&E attendance or hospital admission)
Number of subjects: 0
Study 30971261 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5 L
Number of subjects: 0
Study 30971261 — intervention group
Group type: EXPERIMENTAL
Intervention: AQL-5D (preference-based measure derived from AQLQ)
Number of subjects: 0
Study 30971261 — intervention group
Group type: EXPERIMENTAL
Intervention: TTO
Number of subjects: 0
Study 30971304 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS in addition to conscious sedation and paracervical block
Number of subjects: 0
Study 30971304 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS in addition to conscious sedation and paracervical block
Number of subjects: 0
Study 30971318 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study 30971318 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 0
Study 30971318 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 30971319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal denial of pregnancy (case group)
Number of subjects: 140
Study 30971319 — intervention group
Group type: COMPARATOR
Intervention: No maternal denial of pregnancy (control group)
Number of subjects: 140
Study 30972619 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (n=919)
Number of subjects: 2032
Study 30972619 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=1113)
Number of subjects: 2032
Study 30972640 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up fecal microbiota transplantation (single, multiple, followed by immunosuppressants)
Number of subjects: 109
Study 30972640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation procedures
Number of subjects: 109
Study 30972640 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of microbiota from stool using automatic system
Number of subjects: 109
Study 30972640 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery method of colonic transendoscopic enteral tubing
Number of subjects: 109
Study 30972912 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a for ≥ 24 weeks
Number of subjects: 1669
Study 30972912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analog (with peginterferon alfa-2a)
Number of subjects: 1669
Study 30972912 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1669
Study 30973338 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote counseling by dietitians using a mobile phone app
Number of subjects: 43
Study 30973373 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 20 mg twice daily and Pazopanib 600 mg daily (DL 2)
Number of subjects: 27
Study 30973745 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance Use Disorder (SUD)
Number of subjects: 0
Study 30973745 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 0
Study 30974509 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg positivity
Number of subjects: 2241
Study 30974509 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2241
Study 30974509 — intervention group
Group type: EXPERIMENTAL
Intervention: Race
Number of subjects: 2241
Study 30974509 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV genotype
Number of subjects: 2241
Study 30974509 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal core promoter and precore variants
Number of subjects: 2241
Study 30975005 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention for acute myocardial infarction
Number of subjects: 11969
Study 30975005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care unit usage for non-STEMI patients
Number of subjects: 11969
Study 30975005 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge costs for all patients
Number of subjects: 11969
Study 30975126 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention in a Community-Clinical Linkage model
Number of subjects: 0
Study 30975126 — intervention group
Group type: COMPARATOR
Intervention: Matched non-participants (control group)
Number of subjects: 0
Study 30975201 — intervention group
Group type: EXPERIMENTAL
Intervention: ATOR-1015
Number of subjects: 0
Study 30975203 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status assessment using plasma ferritin and soluble transferrin receptor (sTfR) measurements.
Number of subjects: 985
Study 30975203 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma sTfR in women with severe iron depletion compared to those with iron sufficiency.
Number of subjects: 985
Study 30975203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for modest and severe iron depletion identified through multivariable ordinal logistic regression.
Number of subjects: 985
Study 30975567 — intervention group
Group type: EXPERIMENTAL
Intervention: Shingrix
Number of subjects: 0
Study 30975567 — intervention group
Group type: COMPARATOR
Intervention: Varilrix
Number of subjects: 0
Study 30975630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m²), fluorouracil, and vincristine, administered in two 21-day cycles within 42 days of resection.
Number of subjects: 49
Study 30975630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, fluorouracil, and vincristine (adjuvant chemotherapy).
Number of subjects: 49
Study 30975680 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI patients
Number of subjects: 19732
Study 30975684 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mTBI
Number of subjects: 19732
Study 30975699 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via nasal cannula
Number of subjects: 1039
Study 30975699 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 1039
Study 30976125 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 10119
Study 30976125 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 10119
Study 30976125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation with rocuronium
Number of subjects: 10119
Study 30976125 — intervention group
Group type: COMPARATOR
Intervention: Intubation with suxamethonium
Number of subjects: 10119
Study 30976202 — intervention group
Group type: EXPERIMENTAL
Intervention: High ZEB1 protein expression
Number of subjects: 75
Study 30976292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal view (IAV) score based on observed factors
Number of subjects: 283
Study 30976292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal view (IAV) factors
Number of subjects: 283
Study 30976292 — intervention group
Group type: EXPERIMENTAL
Intervention: IAV score
Number of subjects: 283
Study 30976651 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 21
Study 30976651 — intervention group
Group type: EXPERIMENTAL
Intervention: High molecular weight von Willebrand factor (HMW-vWF) multimers
Number of subjects: 21
Study 30976780 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation defined as CRP >5 mg/L or AGP >1 g/L, or both
Number of subjects: 451
Study 30976780 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal models adjusting for inflammation
Number of subjects: 451
Study 30976780 — intervention group
Group type: COMPARATOR
Intervention: CS models
Number of subjects: 451
Study 30976898 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy using esophageal Doppler monitoring (EDM) during laparoscopic adrenalectomy for PCC patients.
Number of subjects: 15
Study 30976898 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIAT patients) receiving standard care without EDM monitoring.
Number of subjects: 15
Study 30976898 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC patients receiving goal-directed fluid therapy using EDM.
Number of subjects: 15
Study 30976898 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC patients post-tumor resection.
Number of subjects: 15
Study 30977682 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0
Study 30977682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30977792 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative atrial fibrillation (POAF)
Number of subjects: 96
Study 30977792 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative C-reactive protein (CRP)
Number of subjects: 96
Study 30977792 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index
Number of subjects: 96
Study 30977792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic clamp time
Number of subjects: 96
Study 30977792 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term atrial fibrillation (LTAF)
Number of subjects: 96
Study 30977945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P)
Number of subjects: 2522
Study 30978179 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Level Interventions for Pre-eclampsia (CLIP) intervention with supplementary hypertension-oriented care and standardised blood pressure measurement.
Number of subjects: 28420
Study 30978179 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational hypertension diagnosis at first presentation with elevated BP.
Number of subjects: 28420
Study 30978179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia diagnosis.
Number of subjects: 28420
Study 30978179 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension diagnosis.
Number of subjects: 28420
Study 30978179 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of additional diagnoses of hypertension and related complications from household surveys or facility record review.
Number of subjects: 28420
Study 30978404 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy
Number of subjects: 0
Study 30978404 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30978502 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 34
Study 30978536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth salts (240 mg) combined with proton pump inhibitors (esomeprazole, omeprazole, pantoprazole, rabeprazole), amoxicillin (1 g), and clarithromycin (500 mg), all taken twice daily for 14 days.
Number of subjects: 1141
Study 30978536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth salts (240 mg) combined with standard triple therapy.
Number of subjects: 1141
Study 30978536 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy without bismuth (not explicitly mentioned in the abstract).
Number of subjects: 1141
Study 30978536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth salts with a double dose of proton pump inhibitor (equivalent to 40 mg omeprazole).
Number of subjects: 1141
Study 30978536 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day duration of treatment.
Number of subjects: 1141
Study 30978536 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment compliance.
Number of subjects: 1141
Study 30978536 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events occurred in 36% of patients; 76% of these events were mild, with a mean duration of 6 days.
Number of subjects: 1141
Study 30979361 — intervention group
Group type: EXPERIMENTAL
Intervention: Surprise Question (SQ) response [Yes/No]
Number of subjects: 600
Study 30979361 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative Surprise Question response [Yes/No]
Number of subjects: 600
Study 30979361 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage probability of dying [0% - 100%]
Number of subjects: 600
Study 30979361 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed treatment plan [multiple choice]
Number of subjects: 600
Study 30979546 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory support
Number of subjects: 48
Study 30979546 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilator-free survival
Number of subjects: 48
Study 30979546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6-dependent seizures and respiratory distress/failure
Number of subjects: 48
Study 30979546 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase activity
Number of subjects: 48
Study 30979546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest deformity, respiratory distress, respiratory failure, failure to thrive, elevated calcium levels
Number of subjects: 48
Study 30979546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 48
Study 30979737 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 71
Study 30979811 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm delivery
Number of subjects: 0
Study 30979811 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) (<2500 g)
Number of subjects: 0
Study 30979811 — intervention group
Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA)
Number of subjects: 0
Study 30979811 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-term delivery
Number of subjects: 0
Study 30979843 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleterious somatic variants in OC predisposition genes
Number of subjects: 473
Study 30979860 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHD1
Number of subjects: 103
Study 30979860 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHD2
Number of subjects: 103
Study 30979860 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap between FSHD1 and FSHD2
Number of subjects: 103
Study 30980071 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 53
Study 30980576 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir + dasabuvir with low-dose ribavirin for 12 weeks
Number of subjects: 105
Study 30980734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostemsavir (FTR) 600 mg twice daily
Number of subjects: 32
Study 30980734 — intervention group
Group type: COMPARATOR
Intervention: Control (without Fostemsavir)
Number of subjects: 32
Study 30980827 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implants
Number of subjects: 350
Study 30981000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IBD
Number of subjects: 32
Study 30981000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis
Number of subjects: 32